Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D
Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Am J Ment Retard. 2003 Nov;108(6):367-72. doi: 10.1352/0895-8017(2003)108<367:EODOCF>2.0.CO;2.
Our goal in this study was to determine whether donepezil, an acetylcholinesterase inhibitor, would improve cognitive functioning in 19 subjects with Down syndrome and no dementia. They were assigned to either a donepezil or placebo group. Cognitive functioning and caregiver ratings were measured at baseline, 4 weeks, and 12 weeks. With the exception of one area (language), no improvement was noted in any of the cognitive subtests, behavioral scores, or caregiver ratings. Subjects in the donepezil group showed an improvement in language scores compared to subjects in the placebo group. The results suggest that donepezil may improve language performance in subjects with Down syndrome and no dementia, but further studies need to be done on a larger group to confirm this result.
我们这项研究的目的是确定乙酰胆碱酯酶抑制剂多奈哌齐是否能改善19名无痴呆症的唐氏综合征患者的认知功能。他们被分为多奈哌齐组或安慰剂组。在基线、4周和12周时测量认知功能和照料者评分。除了一个领域（语言）外，在任何认知子测试、行为评分或照料者评分中均未发现改善。与安慰剂组的受试者相比，多奈哌齐组的受试者语言评分有所提高。结果表明，多奈哌齐可能改善无痴呆症的唐氏综合征患者的语言表现，但需要在更大规模的群体上进行进一步研究以证实这一结果。
